Notable Labs, LTD

Notable Labs, Ltd. will be delisted from the Nasdaq Stock Market after filing for Chapter 7 bankruptcy.

Notable Labs, Ltd. and its subsidiaries have filed for Chapter 7 bankruptcy, leading to the resignation of the board of directors and termination of key executives.

Notable Labs is exploring strategic alternatives, pausing a Phase 2 clinical trial, and reducing its workforce by approximately 65% to conserve cash.

Notable Labs has appointed Kaile A. Zagger as its Interim Chief Executive Officer and Chief Restructuring Officer, effective September 16, 2024.

Notable Labs has announced the resignation of its CEO, Thomas Bock, and the appointment of Joseph Wagner as interim CEO, while affirming plans to initiate a Phase 2 program for volasertib.

Notable Labs has released a white paper detailing the design of its Phase 2 trial for Volasertib in relapsed/refractory Acute Myeloid Leukemia (AML), incorporating enhanced antibiotic prophylaxis, tailored dosing, and its Predictive Medicine Platform.

Notable Labs reports its financial results for the second quarter ended June 30, 2024, highlighting ongoing efforts in predictive medicine development.

Notable Labs reports its Q1 2024 financial results, highlighting a net loss and expressing concerns about its ability to continue as a going concern without additional funding.

Notable Labs, a clinical-stage platform therapeutics company, released its 2023 financial results and provided an update on its business, including the progress of its predictive precision medicine platform and clinical programs.

Director Tuomo Patsi acquired 65,247 ordinary shares of Notable Labs, Ltd. through a restricted stock grant on May 8, 2024.

Joseph P. Wagner, Chief Scientific Officer of Notable Labs, Ltd., acquired 200,000 stock options on May 8, 2024, according to a recent SEC filing.

Director Michele Galen reports acquiring 40,247 ordinary shares of Notable Labs, Ltd. through a grant of restricted shares.

Director Thomas Dubin acquired 40,247 restricted shares in Notable Labs, Ltd. on May 8, 2024, which vest in two equal annual installments.

Director Thomas Graney reports acquiring 40,247 ordinary shares of Notable Labs, Ltd. through a grant of restricted shares.

Director Peter Feinberg acquired 40,247 ordinary shares of Notable Labs, Ltd. on May 8, 2024, through a grant of restricted shares.

Notable Labs, Ltd. files an amended registration statement for a best-efforts offering of units consisting of ordinary shares (or pre-funded warrants) and Tranche A warrants.

Notable Labs, Ltd. files an amendment related to a prefunded ordinary share purchase warrant, detailing terms, definitions, and exercise conditions.

Notable Labs, a clinical-stage platform therapeutics company, is offering ordinary shares and warrants in a best-efforts offering.

Notable Labs is seeking to raise up to $15 million through a best-efforts offering of ordinary shares and warrants to fund research and development and general corporate purposes.